Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A—real-world data from a preliminary cohort study

BackgroundThis preliminary retrospective cohort study investigates the potential additive prophylactic effect of erenumab, a fully human monoclonal antibody that blocks the calcitonin gene-related peptide receptor, in combination with ongoing onabotulinumtoxin A (onaBoNT-A) treatment in patients suf...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tristan Koelsche, Petyo Nikolov, Valeria Koska, Jens Ingwersen, Robin Jansen, Ercan Arat, Sven G. Meuth, Philipp Albrecht, John-Ih Lee
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-06-01
coleção:	Frontiers in Neurology
Assuntos:	migraine disability assessment combination therapy of erenumab and onabotulinumtoxin A prophylactic combination therapy retrospective cohort study quality of life in migraine
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fneur.2024.1370503/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!